Array biopharma inc stock
par value $0.001 per share, of Array BioPharma Inc. (“Array”) multiplied by the offer price of $48.00 per share, (ii) the net offer price for 15,982,995 shares issuable pursuant to outstanding stock options with an exercise price less than $48.00 per share (which is calculated by multiplying the number of shares underlying such outstanding Array BioPharma Inc. Company Information | Drugs.com Drugs Associated with Array BioPharma Inc. Array BioPharma Inc. manufactures, markets and/or distributes more than 2 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is … Finny - Array BioPharma Inc. (ARRY) Stock Performance ... Array BioPharma (ARRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Array BioPharma | Crunchbase
Array BioPharma Inc., a Subsidiary of Pfizer Inc ...
17 Jun 2019 Array BioPharma Inc., a biopharmaceutical company, focuses on the outstanding shares of Array common stock for $48 per share in cash for Security and exchange commission filings for Array Biopharma Inc. Insider trades , quarterly, and annual reports. Array Biopharma Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their Stock Style, —. 17 Jun 2019 Shares of Boulder, Colorado-based Array BioPharma Inc. surged 60 IVOL: First -of-its-Kind ETF listed on the New York Stock Exchange. 17 Jun 2019 Pfizer said Monday it will pay $48 per share in cash for Array, whose product a premium of 62 percent to the stock's closing price of $29.59 on Friday. Shares of Boulder, Colorado-based Array BioPharma Inc. surged 60 17 Jun 2019 Array BioPharma Inc. (NASDAQ: ARRY) shares shot up on Monday after This buyout premium also represents an all-time high for the stock
10-Q: ARRAY BIOPHARMA INC - MarketWatch
17 Jun 2019 Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, Array BioPharma Valuation and Funding. Merger/ Stock, Series B, Series A.
17 Jun 2019 Pfizer's offer of $48 per share represents a premium of 62 percent to the stock's closing price of $29.59 on Friday. Shares of Array BioPharma Inc. 6 Feb 2019 Array BioPharma Inc. ARRY was a big mover last session, as the company saw its shares rise nearly 11% on the day. The move came on solid Array BioPharma Inc. (ARRY) Stock Analysis & News ... Get breaking news and analysis on Array BioPharma Inc. (ARRY) stock, price quote and chart, trading and investing tools. ARRY Stock Quote - Array BioPharma Inc - Bloomberg Markets Stock analysis for Array BioPharma Inc (ARRY) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Array BioPharma - ARRY - Stock Price & News | The Motley Fool
17 Jun 2019 Pfizer Inc. will buy Array BioPharma Inc. for $10.6 billion to gain its promising new medicines for cancer, which could end or limit the use of
Check out our ARRY stock analysis, current ARRY quote, charts, and historical prices for Array Biopharma Inc stock ARRY Interactive Stock Chart | Array BioPharma Inc. Stock ... At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. ARRY Institutional Ownership - Array BioPharma, Inc. Stock Array BioPharma, Inc. (NASDAQ:ARRY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. ARRY Stock News and Price / Array BioPharma, Inc. - Stock ...
A multitude of indications on the Array Biopharma Inc (NASDAQ:ARRY) stock chart is suggesting that higher ARRY stock prices are on the horizon. Here's the full story.